UltraGreen.ai Limited, a Singapore-based fluorescence-guided surgical technologies and precision healthcare solutions provider, has received regulatory approval in Singapore for Verdye, an indocyanine green (ICG) injection used in fluorescence-guided surgery.
In a statement on Tuesday, the healthcare company said the approval supports its Southeast Asia growth strategy by expanding its market and strengthening its presence in the region. Singapore is a key healthcare hub with influence on the adoption of advanced surgical technologies across Southeast Asia.
The approval allows UltraGreen.ai to advance commercialization efforts, expand partnerships with healthcare institutions, and support the clinical use of fluorescence-guided surgery. The technique using ICG is applied across multiple surgical fields, including oncology, colorectal, reconstructive, and vascular procedures.
The move aligns with its broader strategy to develop an integrated fluorescence-guided surgery platform combining pharmaceutical products, imaging hardware, and AI-powered data systems, UltraGreen.ai said. The development can support surgical decision-making and standardization.
Ravi Sajwan, CEO of UltraGreen.ai, emphasized the approval reflects the company’s regulatory progress and regional strategy, adding that Singapore serves as an important reference point for clinical adoption across Southeast Asia.
The development follows the company’s recent initial public offering and a prior approval of Verdye in the Philippines. Verdye is now approved in 41 countries, while the IC-Flow imaging system is cleared in 45 markets.